| Title |
Fatal bleeding in a nasopharyngeal carcinoma patient after concurrent chemoradiation plus cetuximab: a case report
|
|---|---|
| Published in |
OncoTargets and therapy, June 2013
|
| DOI | 10.2147/ott.s44214 |
| Pubmed ID | |
| Authors |
LingYan Zheng, SenXiang Yan, DanFang Yan, JingSong Yang, YiXiang Wang |
| Abstract |
Carotid blowout syndrome (CBS) refers to the clinical signs and symptoms related to rupture of the carotid artery (CA) and its branches, which mainly results from malignant invasion of the CA by head and neck cancers. Here, we present a 46-year-old male patient who suffered from nasopharyngeal carcinoma and was treated with a combination of chemoradiation and cetuximab. The patient was stage IVb (T4N2M0) clinically, with encasement of the left internal carotid artery, as shown on pretreatment magnetic resonance imaging. Three months after completion of radiotherapy, the patient died of sudden massive epistaxis. CBS is a lethal complication of nasopharyngeal carcinoma, so the risk of CBS should be carefully assessed in patients with imaging showing CA encasement. Till now, the precise prediction and prevention of CBS remain to be explored. |
Mendeley readers
The data shown below were compiled from readership statistics for 7 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 7 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 3 | 43% |
| Student > Bachelor | 1 | 14% |
| Other | 1 | 14% |
| Professor > Associate Professor | 1 | 14% |
| Student > Postgraduate | 1 | 14% |
| Other | 0 | 0% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 71% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 14% |
| Unknown | 1 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 January 2014.
All research outputs
#6,753,656
of 25,373,627 outputs
Outputs from OncoTargets and therapy
#336
of 3,016 outputs
Outputs of similar age
#53,479
of 206,481 outputs
Outputs of similar age from OncoTargets and therapy
#13
of 45 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,481 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 45 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.